39 related articles for article (PubMed ID: 34181499)
1. Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment.
Zhang Z; Zhang S; Zhang F; Zhang Q; Wei H; Xiu R; Zhao Y; Sui M
Biol Trace Elem Res; 2024 Jan; 202(1):122-132. PubMed ID: 37097388
[TBL] [Abstract][Full Text] [Related]
2. Anthropometric measures and arsenic methylation among pregnant women in rural northern Bangladesh.
Smith TJS; Navas-Acien A; Baker S; Kok C; Kruczynski K; Avolio LN; Pisanic N; Randad PR; Fry RC; Goessler W; van Geen A; Buckley JP; Rahman MH; Ali H; Haque R; Shaikh S; Siddiqua TJ; Schulze K; West KP; Labrique AB; Heaney CD
Environ Res; 2023 Oct; 234():116453. PubMed ID: 37343752
[TBL] [Abstract][Full Text] [Related]
3. Associations of arsenic exposure and arsenic metabolism with the risk of non-alcoholic fatty liver disease.
Liu Y; Li W; Zhang J; Yan Y; Zhou Q; Liu Q; Guan Y; Zhao Z; An J; Cheng X; He M
Int J Hyg Environ Health; 2024 Apr; 257():114342. PubMed ID: 38401403
[TBL] [Abstract][Full Text] [Related]
4. Physical activity, body mass index and arsenic metabolism among Mexican women.
Gamboa-Loira B; Cebrián ME; López-Carrillo L
Environ Res; 2021 Apr; 195():110869. PubMed ID: 33581084
[TBL] [Abstract][Full Text] [Related]
5. Positive Association of Urinary Dimethylarsinic Acid (DMA
Zhang K; Yin Y; Lv M; Zhang X; Zhang M; Cui J; Guan Z; Liu X; Liu Y; Gao Y; Yang Y
Toxics; 2024 Jan; 12(1):. PubMed ID: 38251038
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell-free DNA in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Fujihara J; Nishimoto N; Takeshita H
Ann Clin Biochem; 2023 Nov; ():45632231216596. PubMed ID: 37944991
[TBL] [Abstract][Full Text] [Related]
7. Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report.
Emmons GS; Steingart RH; Stewart JA; Mertens WC
J Med Case Rep; 2012 Oct; 6():355. PubMed ID: 23078653
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of acute promyelocytic leukemia in a patient under hemodialysis with arsenic trioxide.
Hashimoto A; Tanaka Y; Ishikawa T; Shinzato I
Clin Case Rep; 2021 Jul; 9(7):e04417. PubMed ID: 34322242
[TBL] [Abstract][Full Text] [Related]
9. Arsenic toxicity manifesting as profuse watery diarrhea during induction therapy for acute promyelocytic leukemia.
Ott A; Venkataraman V; Badran YR; Goldman R; Spasic S; Vyas DA; Amrein P; McAfee S; Brunner A; Fathi AT; Narayan R
Clin Case Rep; 2021 May; 9(5):e04115. PubMed ID: 34026155
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of acute promyelocytic leukemia in a patient undergoing hemodialysis with arsenic trioxide.
Hashimoto A; Tanaka Y; Shinzato I
Clin Case Rep; 2021 Jul; 9(7):e04300. PubMed ID: 34322239
[TBL] [Abstract][Full Text] [Related]
11. Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
Loh Z; Ashby M; Van Veldhuizen E; Li W; Chee A; Aung W; Lavrukhina Y; Mason G; Pelly T; Nedumannil R; Kosciejew S; Mokoonlall M; Lim J; Calov G; Butler L; Hillebrand P; Beekman A; Rathnasekara GK; Raj S; Zhang C; Yao Y; Iland H; Grigg A
Br J Haematol; 2024 Jan; ():. PubMed ID: 38198799
[TBL] [Abstract][Full Text] [Related]
12. Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy.
Ghiaur A; Doran C; Gaman MA; Ionescu B; Tatic A; Cirstea M; Stancioaica MC; Hirjan R; Coriu D
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539495
[TBL] [Abstract][Full Text] [Related]
13. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.
Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J
Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140
[TBL] [Abstract][Full Text] [Related]
14. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
[TBL] [Abstract][Full Text] [Related]
15. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
[TBL] [Abstract][Full Text] [Related]
16. The simpler, the better: oral arsenic for acute promyelocytic leukemia.
Zhu HH; Hu J; Lo-Coco F; Jin J
Blood; 2019 Aug; 134(7):597-605. PubMed ID: 31113776
[TBL] [Abstract][Full Text] [Related]
17. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
18. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
